Oral fluid for the detection of drugs of abuse using immunoassay and LC-MS/MS

Bioanalysis

Volumn 5, Issue 12, 2013, Pages 1555-1569

  Moore, Christine ^a   Crouch, Dennis ^b  

^a Immunalysis Corporation   (United States)

^b Utah Toxicology Expert Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; BENZODIAZEPINE DERIVATIVE; BENZOYLECGONINE; CANNABINOID; CANNABIS; COCAINE; CODEINE; DESIGNER DRUG; METHAMPHETAMINE; MORPHINE; NORCODEINE; OPIATE; OXYCODONE; PHENCYCLIDINE; TETRAHYDROCANNABINOL;

ACCREDITATION; ARTICLE; BLOOD ANALYSIS; CROSS REACTION; DRUG ABUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; GAS CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; LABORATORY DEVICE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PRESERVATION AND STORAGE; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS;

ANALGESICS, OPIOID; CANNABIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COCAINE; HUMANS; IMMUNOASSAY; PHENCYCLIDINE; SALIVA; SPECIMEN HANDLING; STREET DRUGS; TANDEM MASS SPECTROMETRY;

EID: 84879615315     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.115     Document Type: Article

References (76)

1. Lacey JH, Kelley-Baker T, Furr-Holden CDM et al. 2007 National Roadside Survey of Alcohol and Drug Use by Drivers: Drug Results. US Department of Transportation, National Highway Traffic Safety Administration, Washington, DC, USA (2009).
2. Cooper G, Moore C, George C, Pichini S. Guidelines for European workplace drug testing in oral fluid. Drug Test Anal. 3, 269-276 (2011).
3. Department of Health and Human Services (Substance Abuse and Mental Health Service Administration). Proposed revisions to the mandatory guidelines for federal workplace drug testing programs. Federal Register 69, 19673-19732 (2004).
4. Crouch DJ. Oral fluid collection: the neglected variable in oral fluid testing. Forensic Sci. Int. 150(2-3), 165-73 (2005).
5. Drummer OH. Introduction and review of collection techniques and applications of drug testing of oral fluid. Ther. Drug Monit. 30(2), 203-206 (2008).
6. Milman G, Schwope DM, Schwilke EW et al. Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral ?9- tetrahydrocannabinol administration. Clin. Chem. 57(11), 1597-1606 (2011).
7. Langel K, Engblom C, Pehrsson A, Gunnar T, Ariniemi K, Lillsunde P. Drug testing in oral fluid-evaluation of sample collection devices. J. Anal. Toxicol. 32(6), 393-401 (2008).
8. Lee D, Milman G, Schwope DM, Barnes AJ, Gorelick DA, Huestis MA. Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. Clin. Chem. 58(7), 1101-1109 (2012).
9. Garnier M, Coulter C, Moore C. Selection of an immunoassay screening cutoff concentration for opioids in oral fluid. J. Anal. Toxicol. 35(6), 369-374 (2011).
10. Coulter C, Taruc M, Tuyay J, Moore C. Antidepressant drugs in oral fluid using liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 34(2), 64-72 (2010).
11. Schwope DM, Milman G, Huestis MA. Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid. Clin. Chem. 56(6), 1007-1014 (2010).
12. Moore C. Oral fluid and hair in workplace drug testing programs: new technology for immunoassays. Drug Test Anal. 3(3) 166-168 (2011).
13. Ly BT, Thornton SL, Bunon C, Stone JA, Wu AH. False-positive urine phencyclidine immunoassay screen result caused by interference by tramadol and its metabolites. Ann. Emerg. Med. 59(6), 545-547(2012).
14. Baron JM, Griggs DA, Nixon AL, Long WH, Flood JG. The trazodone metabolite meta-chlorophenylpiperazine can cause false-positive urine amphetamine immunoassay results. J. Anal. Toxicol. 35(6), 364-368 (2011).
15. Tuyay J, Coulter C, Rodrigues W, Moore C. Disposition of opioids in oral fluid: Importance of chromatography and mass spectral transitions in LC-MS/MS. Drug Test Anal. 4(6), 395-401 (2012).
16. Crooks CR, Brown S. Roche DAT immunoassay: sensitivity and specificity testing for amphetamines, cocaine, and opiates in oral fluid. J. Anal. Toxicol. 34(2), 103-109 (2010).
17. Drummer OH. Drug testing in oral fluid. Clin. Biochem. Rev. 27(3), 147-159 (2006).
18. Bosker W, Huestis MH. Oral fluid testing for drugs of abuse. Clin. Chem. 55, 1910-1931 (2009).
19. Simonsen KW, Sttentoft A, Hels T, Bernhoft IM, Rasmussen BS, Linnet K. Presence of psychoactive substances in oral fluid from randomly selected drivers in Denmark. Forens. Sci. Int. 221(1-3), 33-38 (2012).
20. Desrosiers NA, Lee D, Schwope DM et al. On-site test for cannabinoids in oral fluid. Clin. Chem. 58(10), 1418-1425 (2012).
21. Chassaing C, Robinson S. Turbulent flow chromatography: an evolving solution for bioanalysis. Chromatogr. Today 20-24 (2009).
22. Badawi N, Simonsen KW, Steentoft A, Bernhoft IM, Linnet K. Simultaneous screening and quantification of 29 drugs of abuse in oral fluid by solid-phase extraction and ultraperformance LC-MS/MS. Clin. Chem. 55(11), 2004-2018 (2009).
23. Strano-Rossi S, Anzillotti L, Castrignano E et al. UHPLC-ESI-MS/MS method for direct analysis of drugs of abuse in oral fluid for DUID assessment. Anal. Bioanal. Chem. 401(2), 609-624 (2011).
24. Piccard P, Tremblay P. LDTD-MS/MS in 1.8 sec with RSD of 2.4%: paracetamol in human plasma crash. Application Note 0708 (2008).
25. Heudi O, Barteau S, Piccard P, Tremblay P, Picard F, Kretz O. Laser diode thermal desorption-positive mode atmospheric pressure chemical ionization tandem mass spectrometry for the ultra-fast quantitation of a pharmaceutical compound in human plasma. J. Pharm. Biomed. Anal. 54(5), 1088-1095 (2011).
26. Quintela O, Andrenyak DM, Hoggan AM, Crouch DJ. A validated method for the detection of delta 9-tetrahydrocannabinol and 11-nor-9-carboxy- delta 9-tetrahydrocannabinol in oral fluid samples by liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry. J. Anal. Toxicol. 31(3), 157-164 (2007).
27. ElSohly MA, Gul W, ElSohly KE, Avula B, Kahn IA. LC-MS (TOF) analysis method for benzodiazepines in urine samples from alleged drug-facilitated sexual victims. J. Anal. Toxicol. 30, 596-600 (2006).
28. Hopfgartner G, Varesio E, Tschäppät V, Grivet C, Bourgogne E, Leuthold LA. Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules. J. Mass Spectrom. 39(8), 845-855 (2004).
29. Concheiro M, de Castro A, Quintela O, Cruz A, Lopez-Rivadulla M. Confirmation by LC-MS of drugs in oral fluid obtained from roadside testing. Forens. Sci. Int. 170(2-3), 156-162 (2007).
30. Oiestad EL, Johansen U, Christophersen AS. Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry. Clin. Chem. 53(2), 300-309 (2007).
31. Coulter C, Garnier M, Tuyay J, Orbita J, Moore C. Determination of carisoprodol and meprobamate in oral fluid. J. Anal. Toxicol. 36, 217-220 (2012).
32. Kala SV, Harris SE, Freijo TD, Gerlich S. Validation of analysis of amphetamines, opiates, phencyclidine, cocaine, and benzoylecgonine in oral fluids by liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 32(8), 605-611 (2008).
33. Telepchak M, Hackett J, Elian A. The use of F-SPE/fast LC-MSMS for analyzing low levels of THC in oral swabs. Presented at: American Society of Mass Spectrometry. Salt Lake City UT, USA, 23-25 May 2010.
34. Maurer H. Advances in analytical toxicology: the current role of liquid chromatography-mass spectrometry in drug quantification in blood and oral fluid. Anal. Bioanal. Chem. 38, 110-118 (2005).
35. Heltsley R, DePriest A, Black DL et al. Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens. J. Anal. Toxicol. 36, 75-80 (2012).
36. Wang IT, Feng YT, Chen CY. Determination of 17 illicit drugs in oral fluid using isotope dilution ultra-high performance liquid chromatography/tandem mass spectrometry with three atmospheric pressure ionizations. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878(30), 3095-3105 (2010).
37. Fritch D, Blum K, Nonnemacher S, Haggerty BJ, Sullivan MP, Cone EJ. Identification and quantitation of amphetamines, cocaine, opiates, and phencyclidine in oral fluid by liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 33(9), 569-577 (2009).
38. Allen KR, Azad R, Field HP, Blake DK. Replacement of immunoassay by LC tandem mass spectrometry for the routine measurement of drugs of abuse in oral fluid. Ann. Clin. Biochem. 42, 277-284 (2005).
39. Clauwaert K, Decaestecker T, Mortier K et al. The determination of cocaine, benzoylecgonine and cocaethylene in small-volume oral fluid samples by liquid chromatography-quadrupole-time-of-flight mass spectrometry. J. Anal. Toxicol. 28, 655-659 (2004).
40. Concheiro M, de Castro A, Quintela O, Cruz A, Lopez-Rivadulla M. Determination of illicit and medicinal drug and their metabolites in oral fluid and preserved oral fluid by liquid chromatography mass spectrometry. Anal. Bioanal. Chem. 391, 2329-2338 (2008).
41. Coulter C, Crompton K, Moore C. Detection of phencyclidine in human oral fluid using solid-phase extraction and liquid chromatography with tandem mass spectrometric detection by LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 863, 123-128 (2008).
42. Sergi M, Compagnone D, Curini R et al. Micro-solid phase extraction coupled with high-performance liquid chromatography-tandem mass spectrometry for the determination of stimulants, hallucinogens, ketamine and phencyclidine in oral fluids. Anal. Chim. Acta 675(2), 132-137 (2010).
43. Moore C, Coulter C, Crompton K. Achieving proposed Federal concentrations using reduced specimen volume for the extraction of amphetamines from oral fluid. J. Anal. Toxicol. 31(8), 442-446 (2007).
44. Autry JH. Notice to DHHS/NIDA certified laboratories (PD002). National Institute on Drug Abuse. Division of Applied Research. 12 October 1990.
45. Autry JH. Notice to DHHS/NIDA certified laboratories (PD003). National Institute on Drug Abuse. Division of Applied Research. 19 December 1990.
46. Wood M, De Boeck G, Samyn N et al. Development of a rapid and sensitive method for the quantitation of amphetamines in human plasma and oral fluid by LC-MS-MS. J. Anal. Toxicol. 27, 78-87 (2003).
47. Slawson MH, Crouch DJ, Andrenyak DM, Rollins DE, Lu JK, Bailey PL. Determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma following intravenous and intrathecal morphine administration utilizing HPLC with electrospray tandem mass spectrometry. J. Anal. Toxicol. 23(6), 468-473 (1999).
48. Moore C, Ross W, Coulter C et al. Detection of the marijuana metabolite, 11-nor-?9-tetra-hydrocannabinol-9-carboxylic acid (THC-COOH) in oral fluid specimens, and its contribution to positive results in screening assays. J. Anal. Toxicol. 30(7), 413-418 (2006).
49. Day D , Kuntz DJ, Feldman M, Presley L. Detection of THCA in oral fluid by GC-MS-MS. J. Anal. Toxicol. 30(7), 645-650 (2006).
50. Moore C, Rana S, Coulter C, Day D, Vincent M, Soares J. Detection of conjugated 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in oral fluid. J. Anal. Toxicol. 31(4), 187-194 (2007)
51. Lowe RD, Guild GE, Harpas P et al. Rapid drug detection in oral samples by porous silicon assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 23(22), 3543-3548 (2009).
52. Bylda C, Leinenbach A, Thiele R, Kobold U, Volmer DA. Development of an electrospray LC-MS/MS method for quantification of D9-tetrahydrocannabinol and its main metabolite in oral fluid. Drug Test. Anal. 4(7-8), 668-674 (2012).
53. Lee PD, Chang YJ, Lin KL, Chang YZ. Simultaneous determination of D9-tetrahydrocannabinol and 11-nor-9-carboxy- D9-tetrahydrocannabinol in oral fluid using isotope dilution liquid chromatography tandem mass spectrometry. Anal. Bioanal. Chem. 402, 851-859 (2012).
54. Coulter C, Garnier M, Moore C. Analysis of tetrahydrocannabinol and its metabolite, 11-nor-d9-tetrahydrocannabinol-9-carboxylic acid, in oral fluid using liquid chromatography with tandem mass spectrometry. J. Anal. Toxicol. 36(6), 413-417 (2012).
55. Coulter C, Garnier M, Moore C. Synthetic cannabinoids in oral fluid. J. Anal. Toxicol. 35(7), 424-430 (2011).
56. Kneisel S, Auwärter V, Kempf J. Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry. Drug Test Anal. doi:10.1002/dta.1429 (2012) (Epub ahead of print).
57. Strano-Rossi S, Anzillotti L, Castrignano E, Romolo FS, Chiarotti M. Ultra high performance liquid chromatography-electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, 'spice' and stimulants in oral fluid. J. Chromatogr. A. 1258, 37-42 (2012).
58. Smink BE, Mathijssen MPM, Lusthof KJ, deGier JJ, Egberts ACG, Uges DRA. Comparison of urine and oral fluid as matrices for screening of thirty-three benzodiazepines and benzodiazepine like substances using immunoassay and LC-MS (-MS). J. Anal. Toxicol. 30(7), 478-485 (2006).
59. Moore C, Coulter C, Crompton K, Zumwalt M. Determination of benzodiazepines in oral fluid using LC/MS/MS. J. Anal. Toxicol. 31(9), 596-600 (2007).
60. Ngwa G, Fritch D, Blum K, Newland G. Simultaneous analysis of 14 benzodiazepines in oral fluid using by solid phase extraction and LC-MS-MS. J. Anal. Toxicol. 31, 369-376 (2007).
61. Kintz P, Villian M, Concheiro M, Cirimele V. Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS. Forens. Sci. Int. 150, 213-220 (2005).
62. Jang M, Chang H, Yang W et al. Development of an LC-MS/MS method for the simultaneous determination of 25 benzodiazepines and zolpidem in oral fluid and its application to authentic samples from regular drug users. J. Pharm. Biomed. Anal. 74, 213-222 (2013).
63. Cone EJ, Clark J, Tsanclis L. Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid. J. Anal. Toxicol. 31, 424-433 (2007).
64. Quintela O, Cruz A, de Castro A, Conchiero M, Lopez-Rivadulla M. Liquid chromatography-electrospray ionisation mass spectrometry for the determination of nine benzodiazepines in human plasma and oral fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 825, 63-71 (2005).
65. Concheiro M, Gray TR, Shakleya DM, Huestis MA. High-throughput simultaneous analysis of buprenorphine, methadone, cocaine, opiates, nicotine, and metabolites in oral fluid by liquid chromatography tandem mass spectrometry. Anal. Bioanal. Chem. 398(2), 915-924 (2010).
66. Heltsley R, DePriest A, Black DL et al. Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J. Anal. Toxicol. 35(8), 529-540 (2011).
67. Vindenes V, Yttredal B, Oiestad EL et al. Oral fluid is a viable alternative for monitoring drug abuse: detection of drugs in oral fluid by liquid chromatography-tandem mass spectrometry and comparison to the results from urine samples from patients treated with methadone or buprenorphine. J. Anal. Toxicol. 35(1), 32-39 (2011).
68. Moore C, Kelley-Baker T, Lacey J. Interpretation of oxycodone concentrations in oral fluid. J. Opioid Manag. 8(3), 161-166 (2012).
69. Gray TR, Dams R, Choo RE, Jones HE, Huestis MA. Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence. Forens. Sci Int. 206(1-3), 98-102 (2011).
70. Vogeser M, Seger C. Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin. Chem. 56(8), 1234-1244 (2010).
71. Fox EJ, Twigger S, Allen KR. Criteria for opiate identification using liquid chromatography linked to tandem mass spectrometry: problems in routine practice. Ann. Clin. Biochem. 46, 50-57 (2009).
72. Rosita I.www.transport-research.info
73. ROSITA II.www.rosita.org
74. DRUID.www.druid-project.eu
75. Society of Forensic Toxicologists, SOFT/AAFS Forensic Laboratory Guidelines - 2006.www.soft-tox.org
76. Coulter C, Castro C. Semi-quantitative determination of tramadol in oral fluid utilizing homogeneous enzyme immunoassay (HEIA): comparison with ELISA.www.immunalysis.com/images/stories/labs/Tramadol-oral-fluid-2009.pdf